Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Core Insights - Moleculin Biotech, Inc. has entered into a research agreement with the University of North Carolina at Chapel Hill to conduct preclinical studies on Annamycin for pancreatic cancer treatment [1][2][3] - Annamycin is being evaluated for its ability to enhance tumor delivery compared to existing treatments like Doxil and Free-doxorubicin [2] - The company aims to leverage Annamycin's high affinity for the pancreas and its correlation with poor survival rates in pancreatic cancer patients to expand its clinical applications [3] Company Overview - Moleculin Biotech is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viral infections [1][6] - Annamycin is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with traditional anthracyclines [6][8] - The company is currently conducting a pivotal Phase 2B/3 trial named MIRACLE, evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) [4][8] Research and Development - The preclinical research at UNC will assess the effectiveness of Annamycin in conjunction with novel agents to improve treatment outcomes for pancreatic cancer [1][2] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for treating relapsed or refractory AML and soft tissue sarcoma lung metastases [3][6] - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, including pancreatic cancer [9]